A carregar...
Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual’s glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide is a...
Na minha lista:
| Publicado no: | Diabetes Metab Syndr Obes |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6475096/ https://ncbi.nlm.nih.gov/pubmed/31118715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S174568 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|